Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ASND | INST-CLUSTER | bearish | 4/10 | 32 tracked institutions completely exited their ASND positions in Q2 2026, liquidating $2.41B in aggregate holdings. The | Sep 22, 2026 |
| RDY | 6-K | neutral | 2/10 | Dr. Reddy's Laboratories filed a Form 6-K on September 22, 2026, to notify exchanges of a Board meeting scheduled for Oc | Sep 22, 2026 |
| JUNS | SC 13G | neutral | 4/10 | PharmAla Biotech Holdings Inc. disclosed a 17.3% passive stake in Jupiter Neurosciences via a Schedule 13G filed Septemb | Sep 22, 2026 |
| MEOH | 6-K | bullish | 5/10 | Methanex announced a partial redemption of US$300 million of its 5.125% senior notes due 2027, with a redemption date of | Sep 22, 2026 |
| GSK | 6-K | neutral | 2/10 | GSK plc filed a Form 6-K reporting open-market purchases of ordinary shares and American Depositary Shares by its Non-Ex | Sep 22, 2026 |
| HBIO | SC 13G/A | neutral | 3/10 | Leviticus Partners LP filed an amended Schedule 13G disclosing a 5.2% passive stake in Harvard Bioscience Inc as of Sept | Sep 22, 2026 |
| OPTH | 6-K | neutral | 3/10 | Optimi Health appointed Dr. Michael Blough as Chief Clinical Development Officer, a newly created role overseeing the co | Sep 22, 2026 |
| AIM | PRESS-RELEASE | neutral | 3/10 | AIM ImmunoTech CEO issued a letter to shareholders addressing the recent FDA approval of daraxonrasib for pancreatic can | Sep 22, 2026 |
| ONMD | PRESS-RELEASE | neutral | 4/10 | OneMedNet Corporation announced a multi-year resale agreement with Atropos Health to expand commercial distribution of i | Sep 22, 2026 |
| PALI | PRESS-RELEASE | bullish | 6/10 | Palisade Bio announced FDA clearance of its IND application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-C | Sep 22, 2026 |
| BIAF | 8-K | neutral | 2/10 | bioAffinity Technologies filed an 8-K announcing it will present two posters on its CyPath Lung diagnostic at the NAVREF | Sep 22, 2026 |
| CMPX | 8-K | bearish | 7/10 | Compass Therapeutics disclosed that the FDA recommended conducting an additional trial demonstrating a survival benefit | Sep 22, 2026 |
| QNRX | PRESS-RELEASE | mixed | 5/10 | Quoin Pharmaceuticals announced FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome, the first such designati | Sep 22, 2026 |
| SCYX | 8-K | neutral | 2/10 | SCYNEXIS appointed Steven K. Burke, M.D., a seasoned nephrology drug development executive, to its Board of Directors ef | Sep 22, 2026 |
| PDSB | 8-K | bullish | 6/10 | PDS Biotech announced the publication of Phase 2 VERSATILE-002 trial results for PDS0101 in combination with pembrolizum | Sep 22, 2026 |
| ENLV | 6-K | bullish | 6/10 | Enlivex terminated its securities purchase agreement with the Rain Foundation, canceling a private placement of 66,666,6 | Sep 22, 2026 |
| FLNA | 8-K | bullish | 6/10 | Filana Therapeutics announced that the FDA has lifted the full clinical hold on its IND for simufilam, enabling the comp | Sep 22, 2026 |
| ADAG | 6-K | bullish | 5/10 | Adagene received NMPA clearance to begin a Phase 1 trial of ADG138, a double-masked HER2xCD3 bispecific T-cell engager, | Sep 22, 2026 |
| KZIA | 6-K | bullish | 5/10 | Kazia Therapeutics announced that its licensee Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib for | Sep 22, 2026 |
| RADX | 6-K | neutral | 3/10 | Radiopharm Theranostics filed a Form 6-K with the SEC on September 22, 2026, disclosing that four directors (Bruce Goodw | Sep 22, 2026 |
| PDSB | PRESS-RELEASE | bullish | 7/10 | PDS Biotech published Phase 2 VERSATILE-002 results in JAMA Oncology showing 39.3-month median overall survival in ICI-n | Sep 22, 2026 |
| CLDX | 8-K | bullish | 7/10 | Celldex reported positive topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials of barzolvolimab in chroni | Sep 22, 2026 |
| LXEO | 8-K | bullish | 6/10 | Lexeo Therapeutics (LXEO) entered into a definitive agreement to acquire Mantle Therapeutics Inc. for $8.3 million in up | Sep 22, 2026 |
| LGND | 8-K | neutral | 4/10 | Ligand Pharmaceuticals acquired royalty and milestone payment rights on Santen's Ryjunea (a pediatric myopia treatment a | Sep 22, 2026 |
| VKTX | 8-K | bullish | 7/10 | Viking Therapeutics announced positive topline results from its VK2735-102 maintenance study, demonstrating that patient | Sep 22, 2026 |
| TNXP | 8-K | bullish | 5/10 | Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for TONMYA, effective immediately, addin | Sep 22, 2026 |
| CYPH | 8-K | neutral | 4/10 | Cypherpunk Technologies appointed Amanda Fabiano, a veteran digital asset mining executive, to its board of directors. T | Sep 22, 2026 |
| ZBIO | PRESS-RELEASE | neutral | 4/10 | Zenas BioPharma announced upcoming presentations of new data from the Phase 3 INDIGO open-label extension of obexelimab | Sep 22, 2026 |
| ELDN | PRESS-RELEASE | bullish | 7/10 | Eledon Pharmaceuticals announced FDA Fast Track designation for tegoprubart in kidney transplantation and presented posi | Sep 22, 2026 |
| MDWD | PRESS-RELEASE | bullish | 4/10 | MediWound received an additional $3.3 million from the U.S. Department of War to develop a room-temperature-stable formu | Sep 22, 2026 |